Coya Therapeutics, Inc. COYA
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells ("Tregs"). Tregs are a subpopulation of T-lymphocytes consisting of CD4+CD25high hFOXP3+ cells that suppress inflammatory responses. Tregs were first discovered in 1995 by Dr. Shimon Sakaguchi and since their discovery multiple lines of research have contributed to elucidate Treg biology and its role in health and disease. Dr. Sakaguchi was the 2025 winner of the Nobel Prize in Physiology or Medicine. Tregs and their transcription factors have been shown to be essential to maintaining cellular homeostasis by regulating autoimmune and inflammatory responses and maintaining self-tolerance in mammals. Dysfunctional Tregs underlie numerous disease states, and this cellular dysfunction is driven by the chronic inflammatory environment and high levels of oxidative stress commonly observed in certain diseases. Further, the degree of Treg dysfunction is correlated with the severity and progression of serious and life-threatening conditions. These and other recent advances in the understanding of Treg biology, have made this subset of T-lymphocytes an important potential therapeutic target, which we believe may provide new treatments for serious diseases.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — | — |
| SG&A | $11.4M | $8.9M | $7.8M | $4.8M | $2.3M | — |
| Total operating expenses | $30.5M | $20.8M | $13.9M | $9.8M | $4.9M | — |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M | — |
| Pre-tax income | -$21.2M | -$15.6M | -$7.3M | -$12.2M | — | — |
| Income tax | $3.1K | $720.3K | $723.9K | $0 | — | — |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M | -$4.9M | — |
| EPS, basic | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 | — |
| EPS, diluted | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 | — |
| Shares, diluted (wtd. avg.) | 16.7M | 15.2M | 10.2M | 2.6M | 2.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M | — |
| Total current assets | $49.9M | $44.3M | $41.2M | $7.2M | $4.6M | — |
| Property, plant and equipment | $11.2K | $38.6K | $65.9K | $93.3K | $120.7K | — |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M | — |
| Accounts payable | $1.1M | $1.6M | $1.2M | $1.8M | $857.6K | — |
| Total current liabilities | $5.9M | $3.8M | $5.1M | $3.8M | $1.1M | — |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M | — |
| Retained earnings | -$62.0M | -$40.7M | -$25.9M | -$17.9M | -$5.6M | — |
| Total equity | $43.0M | $39.6M | $35.6M | -$8.4M | $3.6M | $8.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M | — |
| Depreciation and amortisation | $27.4K | $27.4K | $27.4K | $27.4K | $16.1K | — |
| Stock-based compensation | $4.3M | $2.7M | $872.2K | $207.3K | $233.2K | — |
| Investing cash flow | -$1.2M | -$25.0K | -$543.2K | -$525.0K | -$136.8K | — |
| Financing cash flow | $20.4M | $16.0M | $38.4M | $9.4M | -$340.6K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-107281.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $6.0M | $3.6M | $7.9M |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$4.9M | -$12.2M | -$8.0M | -$14.9M | -$21.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |